ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Rocuronium Labatec®:Labatec Pharma SA
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
M03AC09 - Rocuronium BromideATC-DDD Version 2016. Source: WHO
M - Musculo-Skeletal System
 
M03 - Muscle Relaxants

This group comprises peripherally, centrally and directly acting muscle relaxants.
See also G04BD - Drugs for urinary frequency and incontinence.

M03A - Muscle Relaxants, Peripherally Acting Agents

This group comprises peripherally acting muscle relaxants such as curare alkaloids and suxamethonium.
The drugs in this group are mainly used together with anesthetics.

As for other drugs used in general anesthesia (see N01A), no DDDs have been established in this group because the doses used vary substantially.

M03AC - Other Quaternary Ammonium Compounds

Sugammadex indicated for reversal of neuromuscular blockade induced by rocuronium or vecuronium is classified in V03AB - Antidotes.

M03AC09 - Rocuronium Bromide
2025 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home